

# **Myeloma in adults: diagnosis and management**

## **Declarations of interests**

The following members of the Guideline Committee made declarations of interests. All other members of the Committee stated that they had no interests to declare. The conflicts of interest policy (2007) was followed until September 2014, when an [updated policy](#) was published.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Curly Morris	Received reimbursement of travel and subsistence expenses, and registration fee to attend the American Society for Haematology Meeting in Atlanta.	Personal pecuniary Non-specific	Declare and can participate.
Curly Morris	Received financial support from Celgene to attend the International Myeloma Workshop in Kyoto, Japan. Money was paid to Altnagelvin Haematology Laboratory Trust Funds	Non-personal pecuniary Non-specific	Declare and can participate.
Curly Morris	Received financial support from Mundi Pharma to attend the European Blood and Marrow Transplant Meeting in London. Money was paid to Altnagelvin Haematology Laboratory Trust Funds	Non-personal pecuniary Non-specific	Declare and can participate.
Curly Morris	Member of the trial management group and involved in designing the the trial protocol for Myeloma X trial (phase III on the role of a second autologous stem cell transplant in patients with relapsed myeloma following high dose rate chemotherapy and autologous stem cell rescue). Funded by CRUK.	Non-personal pecuniary Specific	Declare and can participate.
Curly Morris	Principal investigator and involved in designing the trial protocol for an Irish Clinical Oncology Research Group (ICORG) sponsored phase II trial of Bortezomib, Adriamycin and Dexamethasone (PAD) in patients with relapsed and refractory myeloma. Costs and free drug from Jansen Cilag.	Non-personal pecuniary Specific	Declare and must withdraw from discussion on topics that include PAD as an intervention.
Curly Morris	Received reimbursement of travel expenses from the organisers for speaking on myeloma to data managers at the	Personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	European Blood and Marrow Transplant meeting		
Curly Morris	The Binding Site Ltd have offered to reimburse travel and subsistence expenses for attendance at their conference in Edinburgh.	Personal pecuniary Non-specific	Declare and can participate.
Curly Morris	Will receive reimbursement of travel and subsistence expenses from EMBT for chairing a session and presenting on maintenance and consolidation post transplant in myeloma patients at their conference in Turin	Personal pecuniary Non-specific	Declare and can participate.
Curly Morris	Will receive support from Celgene to attend the 2015 International Myeloma Workshop.	Personal pecuniary non-specific	Declare and can participate.
Guy Pratt, Clinical Lead	Receives an annual payment from the Binding Site Ltd for being a member of their advisory board and providing general clinical advice. This involves overseeing, as chief investigator, a study recruiting normal blood donors from within the company for control samples.	Personal pecuniary Specific	Declare and must withdraw from discussion on topics which include interventions made by Binding Site Ltd.
Guy Pratt	Received honorarium from Celgene for chairing a meeting on general myeloma issues.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Received honorarium from Janssen for a presentation on Waldenstroms.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Received support for travel, accommodation and subsistence expenses from Binding Site Ltd to attend an educational meeting in Japan.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Received support from the Italian Haematology Society to attend and present a lecture on	Personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	Immunodeficiency in Multiple Myeloma		
Guy Pratt	Chief investigator (and designed trial protocol) for the PICCLE trial (parp inhibitor olaparib in relapsed chronic lymphocytic leukaemia). Astra Zeneca provided free drug support and the trial was supported by Leukaemia Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Principal investigator for the PADIMAC trial (Phase II study of bortezomib, adramycin, dexamethasone (PAD) therapy in previously untreated myeloma patients). Funded by Leukaemia Lymphoma Research	Non-personal pecuniary Specific	Declare and can participate.
Guy Pratt	Principal investigator for the GOYA study (GA-101 +CHOP versus RCHOP chemotherapy in untreated Diffuse Large B-cell NHL). Funded by Roche	Non-personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Principal investigator for the Lilly Myeloma trial (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in relapsed by Myeloma). Funded by Lilly	Non-personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Principal investigator for the Gilead CLL study (A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia).	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	Funded by Gilead		
Guy Pratt	Co-investigator (involved in designing the trial protocol) for the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and can participate.
Guy Pratt	Co-investigator (involved in designing the trial protocol) for the BAP trial (bezafibrate/medroxyprogesteron in chronic lymphocytic leukaemia, acute myeloid leukaemia and non-Hodgkin's lymphoma). Funded by Queen Elizabeth Hospital Trust.	Non-personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Member of the trial management group for a randomised phase II trial R2W in Waldenström's macroglobulinaemia funded by Cancer Research UK. Involved in trial design, protocol amendments and answering clinical queries.	Non-personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Member of the data monitoring committee (checks safety data) for the LenaRIC trial (Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma). Funded by CTAAC	Non-personal pecuniary Specific	Declare and can participate.
Guy Pratt	Member of the data monitoring committee (checks safety data) for HA-1 trial (A phase I clinical trial of the vaccination of healthy	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	human volunteers against the minor histocompatibility antigen (mHA <sub>g</sub> ) HA-1 using a DNA and MVA 'prime/boost' regimen).		
Guy Pratt	Co-author on an evidence based position statement on bendamustine in multiple myeloma, on behalf of the UK Myeloma Forum and Myeloma UK.	Personal non-pecuniary	Declare and can participate.
Guy Pratt	Co-author on an evidence based position statement on maintenance and consolidation in multiple myeloma, on behalf of the UK Myeloma Forum and Myeloma UK.	Personal non-pecuniary	Declare and can participate.
Guy Pratt	Registration fee for attendance at the British Society of Haematology Annual Meeting in Birmingham was paid by Janssen.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Will receive an honorarium for chairing a medical advisory board for Takeda on ixazomib.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Will receive an honorarium for chairing a medical advisory board for Amgen on carfilzomib.	Personal pecuniary Specific	Declare and can participate.
Guy Pratt	Will receive reimbursement of travel and subsistence expenses from the Binding Site Ltd to attend the American Society of Haematology Conference in San Francisco.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Will receive reimbursement of travel and subsistence expenses from The Binding Site Ltd to attend their meeting in Edinburgh.	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Giving a presentation on the management of myeloma for Sebia UK Ltd in Birmingham.	Personal non-pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Guy Pratt	Will receive reimbursement of travel and subsistence expenses from Helena Biosciences Europe for giving a talk on international standards for diagnosis and relapse in myeloma in Barcelona	Personal pecuniary Non-specific	Declare and can participate.
Guy Pratt	Will receive support from Takeda to attend the 2015 International Myeloma Workshop.	Personal pecuniary non-specific	Declare and can participate.
Hamdi Sati	Reimbursed for travel expenses to attend the European Haematology Association annual meeting by Napp Pharmaceuticals	Personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	Local principle investigator for the Myeloma X trial (A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high dose chemotherapy and autologous stem cell rescue). Funded by CRUK	Non-personal pecuniary Specific	Declare and can participate.
Hamdi Sati	Local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and can participate.
Hamdi Sati	Local principle investigator for the MM1 trial (investigating whether adding MLN9708 to the combination of lenalidomide and dexamethasone, improves survival in patients with relapsed myeloma). Funded by Millenium Pharmaceuticals.	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Hamdi Sati	Local principle investigator for the PASS observational study (A non-interventional observational post authorisation safety study of subjects treated with lenalidomide). Funded by Celgene	Non-personal pecuniary Specific	Declare and can participate.
Hamdi Sati	Local principle investigator for the PREAMBLE observational study (non-interventional observational study aimed at understanding the real world effectiveness of novel agents used in treating multiple myeloma and their impact on patient-reported outcomes). Funded by Bristol Myers Squibb.	Non-personal pecuniary Specific	Declare and can participate.
Hamdi Sati	Is a signatory on a myeloma endowment fund (generated by patient donations, no direct contributions from pharmaceutical industry). Used to fund small projects and provide additional resource for ongoing research projects.	Non-personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	Received reimbursement of travel and subsistence expenses from SHIRE for attending the 19th annual EHA meeting in Milan.	Personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	Received reimbursement of travel and subsistence expenses from Celgene to attend the European Multiple Myeloma Academy meeting in Vienna.	Personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	Received reimbursement of travel, subsistence and registration expenses from Bristol-Myers Squibb to attend the American Society of Haematology meeting in San Francisco.	Personal pecuniary Non-specific	Declare and can participate.



<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Hamdi Sati	Is the local principle investigator for a trial examining ixazomib maintenance therapy post Autologous stem cell transplant in newly diagnosed multiple myeloma patients. Trial is sponsored by TAKEDA	Non-personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	HS declared that he has been offered travel and accommodation to attend the 7th international meeting in Edinburgh 16-17 April 2015. Educational sponsorship by Binding site.	personal pecuniary non-specific	Declare and can participate.
Hamdi Sati	HS declared that he has been offered an educational grant covering registration, travel and accommodation to attend the EHA 2015 meeting from BMS.	personal pecuniary non-specific	Declare and can participate.
Hamdi Sati	HS declared that he is the local Principal Investigator for Tourmaline C16021 protocol trial examining the role of Ixazomib maintenance in transplant ineligible patients, sponsored by Takeda.	Non-personal pecuniary Non-specific	Declare and can participate.
Hamdi Sati	Will receive support from Takeda to attend the 2015 International Myeloma Workshop.	Personal pecuniary non-specific	Declare and can participate.
John Snowden	Received an honorarium from MSD for chairing a meeting on antifungal drugs.	Personal pecuniary Specific	Declare and can participate.
John Snowden	Received an honorarium from Celgene for chairing a meeting on myeloma drugs.	Personal pecuniary Specific	Declare and can participate.
John Snowden	Received an honorarium from MSD for attending an advisory board on Posaconazole	Personal pecuniary Specific	Declare and can participate.
John Snowden	Received reimbursement of accommodation, travel, subsistence and	Personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	registration fee from MSD, to attend the American Society for Hematology conference in New Orleans		
John Snowden	Co-applicant on a research grant from Pfizer to investigate characterisation of central brain processing of chemotherapy-induced peripheral neuropathy	Non-personal pecuniary Specific	Declare and must withdraw from discussion on any topics that include pregablin as an intervention.
John Snowden	Local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Local principle investigator for the RIC UCBT trial (Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimen). Funded by The Sue Harris Bone Marrow Trust.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Local principle investigator for the MAC UCBT trial (Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen). Funded by The Sue Harris Bone Marrow Trust.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Local principle investigator for the LenaRIC trial (Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation	Non-personal pecuniary Specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	for multiple myeloma). Funded by CTAAC.		
John Snowden	Local principle investigator for the ProT-4 trial (Phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers). Funded by Leukaemia and Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Local principle investigator for the Myeloma IX trial (A randomised trial comparing second generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy). Funded by MRC	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Local principle investigator for the Myeloma X relapse (intensive) trial (to determine whether a high-dose procedure with autologous transplant is superior to low-dose consolidation therapy following re-induction chemotherapy in patients with relapsed myeloma). Funded by CRUK	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Local principle investigator for the RICAZA trial (Phase II study of the tolerability of adjunctive azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for acute myeloid leukaemia). Funded by Celgene.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Local principle investigator for the Living with advanced relapsed	Non-personal pecuniary Specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	myeloma study (cross sectional observational study to identify preventable and manageable late effects). Funded by Myeloma UK.		
John Snowden	Local principle investigator for a Phase 2, Multi-centre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma related Bone Disease. Funded by Janssen-Cilag Ltd.	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Local principle investigator for the UK Haplo Trial (A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies). Funded by Leukaemia Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Local principle investigator for the HLA Epitope trial (HLA epitope matched platelet transfusion in aplastic anaemia, MDS and AML patients) Funded by NHS Blood and Transplant (NHSBT)	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Principle investigator of a charitable grant from Royal Hallamshire Hospital Leukaemia and Research Fund, for a bolt-on study to Myeloma X, relating to supportive care in myeloma.	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Co-investigator on the MUK5 trial (A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	myeloma). Funded by Myeloma UK		
John Snowden	Co-investigator on the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Co-investigator on the AML 17 trial (Working parties on leukaemia in adults and children trial in AML or high risk MDS 17). Funded by CRUK	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the FiTT study (Investigating the effectiveness of co-morbidity assessment in male patients with myeloma and prostate cancer). Funded by Weston Park Hospital Cancer Charity and Sheffield Teaching Hospitals NHS Foundation trust.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the AML 15 trial (Working parties on leukaemia in adults and children AML trial 15). Funded by MRC.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the AML 16 trial (A programme of development for older patients with AML and high risk MDS). Funded by CRUK.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the MCL MiniAllo trial (Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma). Funded by CRUK, Genzyme Therapeutics, National Institute for Health Research Cancer	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	Network (NRCN).		
John Snowden	Co-investigator on the ORCHARRD trial (Ofatumumab rituximab chemoimmunotherapy ASCT relapsed refractory DLBCL). Funded by GlaxoSmithKline.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the FIGARO trial (A randomised trial of the FLAMSA-BU conditioning regimen in patients with AML and MDS undergoing allogeneic stem cell transplantation). Funded by Leukaemia and Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Co-investigator on the MUK 4 trial (phase II trial of combination treatment with Vorinostat, bortezomib and dexamethasone in patients with relapsed multiple myeloma). Funded by Myeloma UK	Non-personal pecuniary Specific	Declare and can participate.
John Snowden	Co-investigator on the SarCaBon trial (A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain). Funded by MRC	Non-personal pecuniary Non-specific	Declare and can participate.
John Snowden	Member of the UK Myeloma Forum. Involved in writing the evidence-based position statement: 'The use of consolidation and maintenance treatment in myeloma'	Personal non-pecuniary Non-specific	Declare and can participate.
John Snowden	Member of the UK Myeloma Forum has been involved in writing the evidence-based position statement: 'The use of bendamustine in myeloma'	Personal non-pecuniary	Declare and can participate.
John Snowden	Executive member of the UK Myeloma Forum, a non-profit organisation for the support of UK health	Personal non-pecuniary	Declare and can participate.

Name	Interest declared	Type of interest	Decision
	professionals and scientists in the myeloma field.		
John Snowden	Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene: Stradwick S, Freemantle N, Snowden J, Rodrigues F, Brereton N. 2012. Comparative Effectiveness of Lenalidomide plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. Blood (ASH Annual Meeting Abstracts); 120 (21): A4076.	Personal non-pecuniary	Declare and can participate.
John Snowden	Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene: Stradwick S, Freemantle N, Vickers A, Rodrigues F, Monzini M, Brereton N, Snowden. 2013. Comparative Effectiveness of Lenalidomide Plus Dexamethasone Versus Bortezomib Subcutaneous for the Treatment of RRMM. Presented at the 14th International Myeloma Workshop (IMW); Kyoto, Japan; April 3–7.	Personal non-pecuniary	Declare and can participate.
John Snowden	Received reimbursement of travel expenses from the organisers for speaking on quality in transplantation at the Joint Accreditation Committee in Autoimmune Diseases meeting	Personal pecuniary Non-specific	Declare and can participate.
John Snowden	Will receive an honorarium for from Sanofi for attending an advisory board on the mobilising	Personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	agent plerixafor and possibly some future currently unlicensed drugs		
Matthew Jenner	Received an honorarium from Napp Pharmaceuticals for attending an advisory board on bendamustine.	Personal pecuniary Specific	Declare and can participate.
Matthew Jenner	Received payment from Janssen for giving an interview on the delivery of bortezomib in the community setting	Personal pecuniary Specific	Declare and must withdraw from any topics which include bortezomib until December 2014
Matthew Jenner	Received payment from Celgene for chairing a debate on drug treatment of relapsed myeloma.	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene until November 2014.
Matthew Jenner	Received reimbursement of travel and subsistence from Napp Pharmaceuticals to attend the American Society of Haematology meeting in New Orleans	Personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	Received reimbursement of travel and subsistence from Janssen to attend the International Myeloma Workshop in Japan	Personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	Has been offered reimbursement of travel and subsistence expenses from Celgene to attend the European Haematology Association	Personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	Is local principle investigator for the MM1 trial (investigating the effect of adding MLN9708 to the combination of lenalidomide and dexamethasone, improves survival in patients with relapsed myeloma). Funded by Millenium Pharmaceuticals.	Non-personal pecuniary Non-specific	Declare and can participate.



<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Matthew Jenner	Is local principle investigator for the FOCUS trial (Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma). Funded by Onyx Pharmaceuticals	Non-personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	Is local principle investigator for the MUK five trial (phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma). Funded by Myeloma UK	Non-personal pecuniary	Declare and can participate.
Matthew Jenner	Is local principle investigator for the MUK four trial (Phase II Trial of combination treatment with Vorinostat, Bortezomib and Dexamethasone in participants with Relapsed Multiple Myeloma). Funded by Myeloma UK.	Non-personal pecuniary Specific	Declare and can participate.
Matthew Jenner	Is local principle investigator for the Myeloma IX trial (randomised trial comparing second generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy). Funded by the Medical Research Council.	Non-personal pecuniary Specific	Declare and can participate.
Matthew Jenner	Is local principle investigator for the Myeloma X trial (phase III	Non-personal pecuniary Specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	on the role of a second autologous stem cell transplant in patients with relapsed myeloma following high dose rate chemotherapy and autologous stem cell rescue). Funded by Cancer Research UK		
Matthew Jenner	Is local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and can participate.
Matthew Jenner	Signatory for a charitable hospital fund used for education and development for healthcare professionals. No contribution to this fund from the pharmaceutical industry.	Non-personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	Was part of the group who developed evidence based guidelines on myeloma for the BCSH.	Personal non-pecuniary	Declare and can participate.
Matthew Jenner	Is chief investigator for the MUK four trial investigating bortezomib and dexamethasone with vorinostat in relapsed myeloma. Involved in designing the trial protocol. The trial is funded by Myeloma UK.	Non-personal pecuniary Specific	Declare and can participate.
Matthew Jenner	Is local PI for the Pollux study. A randomised phase III study investigating lenalidomide and dexamethasone +/- daratumumab in relapsed myeloma. The study is funded by Janssen.	Non-personal pecuniary	Declare and can participate.
Matthew Jenner	Received reimbursement of travel and subsistence expenses and an	Personal pecuniary	Declare and must withdraw from topics that include

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	honorarium from Amgen Oncology for taking part in an advisory board on carfilzomib.	Specific	carfilzomib as an intervention until September 2015. Chairpersons action that can be asked questions on the evidence base but must not participate in drafting recommendations
Matthew Jenner	Received reimbursement of travel and subsistence expenses and an honorarium from Takeda UK for participating in an advisory board on myeloma	Personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	invited to present on cytogenetics at an educational symposium at the British Society of Haematology Annual Scientific Meeting. MJ will only receive reimbursement of travel expenses	personal pecuniary Non-specific	Declare and can participate.
Matthew Jenner	member of the Myeloma XI trial management group. Myeloma X1 trial is investigating different chemotherapy schedules in newly diagnosed myeloma. These include schedules containing different combinations including thalidomide, lenalidomide, bortezomib and carfilzomib. The trial is primarily funded through CTAAC (Cancer Research UK). Sponsor is University of Leeds.	non-personal pecuniary Specific	Declare and can participate.
Matthew Jenner	MJ declared that he has been offered economy class travel, accommodation and registration for the European Haematology Association Annual Meeting in Vienna, 11-14 June 2015 by Janssen.	personal pecuniary non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Matthew Jenner	MJ declared that he has been offered economy class travel, accommodation and registration for the American Society of Hematology Annual Meeting in Orlando, 5-8th December 2015 by Janssen.	personal pecuniary non-specific	Declare and can participate.
Matthew Streetly	Received payment from Celgene for attending an advisory board on lenalidomide usage in myeloma	Personal pecuniary Specific	Declare and must withdraw from topics which include lenalidomide until June 2014.
Matthew Streetly	Received reimbursement of travel and subsistence expenses from Janssen, for attending the International Myeloma Workshop	Personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	Received payment from Celgene for giving a presentation on "Optimising Myeloma therapy"	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene until November 2014.
Matthew Streetly	Received payment from Celgene for giving presentations on "Pomalidomide Case Histories"	Personal pecuniary Non-specific	Declare and must withdraw from topics which include pomalidomide. Chair persons action that can be asked questions on the evidence base but must not be involved in drafting recommendations.
Matthew Streetly	Received payment from Janssen for giving a presentation on "Transplant: what is the data telling us?". Provided data on induction chemotherapy prior to transplant.	Personal pecuniary Specific	Declare and must withdraw from any topics which include induction chemotherapy until October 2014.
Matthew	Received payment from Celgene for giving a	Personal pecuniary Non-	Declare and must withdraw from

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Streetly	presentation on "Pomalidomide Background: Summary of Recent Data"	specific	topics which include pomalidomide. Chair persons action that can be asked questions on the evidence base but must not be involved in drafting recommendations.
Matthew Streetly	Received payment from Janssen for giving a presentation on "Managing Patient's Expectations"	Personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	Received payment from Celgene for giving a presentation on "Myeloma treatment in South East London"	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene until February 2014.
Matthew Streetly	Had a consultative role on the Burden of Relapse study (a non-treatment related clinical study examining the impact (physical, psychological, economic) of periods of remission in comparison to periods of disease activity). Received payment from Celgene for teleconference participation every few months and review of data	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene until January 2015.
Matthew Streetly	Chief investigator of the MM013 study (Phase 2 multicentre, open-label study to determine the efficacy and safety of pomalidomide in combination with low dose dexamethasone in subjects with relapsed or refractory myeloma). Trial funded by Celgene. Not involved in designing the trial protocol.	Non-personal pecuniary Non-specific	Declare and must withdraw from topics which include pomalidomide. Chair persons action that can be asked questions on the evidence base but must not be involved in drafting recommendations.
Matthew Streetly	Local principle investigator for the PADIMAC study	Non-personal pecuniary	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	(Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT). Funded by Leukaemia & Lymphoma Research	Specific	
Matthew Streetly	Local principle investigator for the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and can participate.
Matthew Streetly	Local principle investigator for the CLARION trial (Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma). Funded by Onyx Therapeutics	Non-personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	Local principle investigator for the CNTO328 trial (Siltuximab (compared with placebo) in Patients With High-risk Smoldering Multiple Myeloma). Funded by Janssen	Non-personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	Local principle investigator for the PASS observational study (A non-interventional observational post authorisation safety study of subjects treated with lenalidomide). Funded by Celgene	Non-personal pecuniary Specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Matthew Streetly	Principle investigator for phase III trial in relapsed myeloma (patients randomised between daratumumab with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone). Trial is funded by Janssen	Non-personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	Written a position statement for the UK Myeloma Forum, about horizon scanning for new agents in myeloma. Statement does not advocate any particular agents.	Personal non-pecuniary	Declare and can participate.
Matthew Streetly	Planning to write a review of the long-term follow up data for a trial on pomalidomide.	Personal non-pecuniary	Declare and can participate.
Matthew Streetly	Is being sponsored to attend the American Society of Haematology Meeting in San Francisco by Janssen. Sponsorship covers flights accommodation and conference registration.	Personal pecuniary Non-specific	Declare and can participate.
Matthew Streetly	accepted a travel award from Janssen Pharmaceuticals to attend the International Myeloma workshop in Rome in September 2015	Personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from MSD was paid to his department for giving a lecture on 'The Science of Symptoms'	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Creative Ceutical was paid to his department for taking part in a teleconference to set up an interview study of quality of life in advanced breast cancer	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Amgen was paid to his	Non-personal pecuniary Non-	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	department for giving a lecture on metastatic bone disease.	specific	
Sam Ahmedzai	An honorarium from Napp Pharmaceuticals was paid to his department for taking part in an advisory board on pain.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Prostrakan was paid to his department for giving a lecture on introduction to nausea and vomiting and its management	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Archimedes was paid to his department for participating in the Archimedes Academy. Participation includes chairing the meeting and helping to select topics and speakers. Also gave a lecture on 'Update on pain control', and took part in a debate on end of life care.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from the World Association for Sleep Medicine was paid to his department for participating in their symposium	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Gruenthal was paid to his department for participating in an advisory board on education and awareness strategies for breakthrough cancer pain	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	An honorarium from Bayer was paid to his department for taking part in a meeting on Sativex	Non-personal pecuniary Specific	Declare and can participate.
Sam Ahmedzai	Chief investigator a study to investigate characterisation of central brain processing of chemotherapy-induced peripheral neuropathy. Funded by Pfizer	Non-personal pecuniary Specific	Declare and must withdraw from topics which include pregablin as an intervention



<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Sam Ahmedzai	Chief investigator for an observational study looking at a new treatment for opioid-induced constipation in cancer patients. Study is funded by Astra Zeneca.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Chief investigator for a study of an experimental new opioid for pain control in cancer patients. Study is funded by Grunenthal	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Chief investigator for a study on a pain killer for cancer and non-cancer patients. Study is funded by Mundi Pharma	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Chief investigator for a study to measure the response to 'Standard laxative treatment' (SLT) in patients with opioid-induced constipation, across several European countries. Study is funded by Mundi Pharma.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Chief investigator for a study to investigate HRQOL of triple negative breast cancer patients. Funded by Creative Ceutical	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Is co-investigator of a trial of an experimental drug to treat bone cancer pain in cancer patients. Trial is funded by the MRC and Astra Zeneca.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Fund holder for the SPORG research group. Money is spent on supportive and palliative care research. No contributions to the fund from pharmaceutical companies	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Received an honorarium and reimbursement of travel expenses from Mundipharma for lectures given during the Pain	Personal pecuniary Specific	Declare and must withdraw from topics which include analgesics as interventions

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	<p>Forum lecture tour in South East Asia and Brazil on:</p> <ul style="list-style-type: none"> <li>• 'pain in special populations'</li> <li>• 'assessing and treating pain in patients with substance abuse concerns'</li> <li>• case presentations on cancer pain, palliative care, neuropathic pain and non-malignant pain.</li> <li>• adequacy of opioid analgesic consumption at country, global and regional levels.</li> </ul>		until April 2015.
Sam Ahmedzai	Received reimbursement of travel and subsistence expenses to attend the European Hyponatraemia Network conference in Zurich from Otsuka	Personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Gave a lecture on 'issues associated with therapeutic opioids - – an evidence-based approach to pain management' at the World Institute of Pain in Maastricht. Travel and subsistence expenses were reimbursed by Mundipharma for attending and an honorarium from Mundipharma was paid to the University of Sheffield	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	Meeting with Chugai to discuss potential research into weight loss in cancer in collaboration with NCRI.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam Ahmedzai	SA declared that he has met with Chugai, in his capacity as chair of the NCRI studies group, to discuss a potential study on weight loss in cancer.	Non-personal pecuniary Non-specific	Declare and can participate.
Sam	Appointed (January 2015)	Personal	Declare and can

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Ahmedzai	by Royal College of Physicians to be their Clinical Lead for the National Care of the Dying Audit. Funded post (1 PA per week) that will be paid direct to SA. Role is to advise and lead the RCP audit team in designing a new format for the National Care of the Dying Audit, overseeing its application and helping RCP to announce and disseminate the results.	pecuniary Non-specific	participate.
Nicola Mulholland	Principle investigator for a trial on biomarkers in lymphoma. Involved in designing the trial protocol. Funded by The Elimination of Leukaemia Fund.	Non-personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Sub-investigator for the ZEST study (Zevalin for older people with diffuse large B cell lymphoma). Funded by Spectrum Pharmaceuticals. Involvement is to administer the drug – not involved in collecting or analysing the data	Non-personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Investigator on a phase I/II study of 177Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin's Lymphoma. Funded by Nordic Nanovector AS	Non-personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Investigator on the NETTER-1 clinical trial. A phase III trial study comparing treatment with 177LU-DOTA0-Tyr3-Oscitrotate to Octreotate LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors. Trial funded by Advanced Accelerator	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	Applications.		
Nicola Mulholland	Investigator on the Foxfire study. An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- interventional radio-embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer	Non-personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	In the process of applying for an ARSAC licence to be an investigator on a phase III, randomised placebo controlled, double blind study of oral ixazomib citrate (MLN9708) maintenance therapy in patients with multiple myeloma following autologous stem cell transplant. Funded by Millenium Pharmaceuticals	Non-personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Will receive an honorarium and reimbursement for travel and subsistence expenses from Sirtex for attending their quest investigator study in Sweden	Personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Will receive reimbursement of travel and subsistence expenses from TheraSphere for attending their training session in Germany	Personal pecuniary Non-specific	Declare and can participate.
Nicola Mulholland	Declared that she has been sponsored to undertake a study on lymphoma. This was classified as personal pecuniary non-specific meaning that NM can participate in discussion on all topics as the guideline is not covering lymphoma.	Non-personal pecuniary Non-specific	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
Andrea Guy	Attended a symposium on pomalidomide organised by Celgene. No fee received. Symposium was to present the data on this drug	Personal non-pecuniary	Declare and can participate.
Andrea Guy	Local principle investigator on myeloma lifestyle study on the management of fatigue. Trial is funded by Cancer Research UK. Celgene have funded a physiotherapist's salary to work on the trial.	Non personal pecuniary Specific	Declare and can participate.
Andrea Guy	Attended the European Multiple Myeloma Academy educational meeting in Vienna. Travel expenses paid by event organisers.	Personal pecuniary Non specific	Declare and can participate.
Monica Morris	Received honorarium for attending a nurse educational event held by Janssen on the supportive care needs of patients with myeloma.	Personal pecuniary Specific	Declare and must withdraw from topics which involve the supportive needs of patients until May 2014.
Monica Morris	Provided advice for Janssen on the content of a nurse educational leaflet on the management of patients on Bortezomib. No payment was received.	Personal non-pecuniary Specific	Declare and can participate.
Monica Morris	Planning to publish the findings of her MSc research into the experience of myeloma family carers. No financial support was provided for the research.	Personal non-pecuniary Specific	Declare and can participate.
Monica Morris	Has been invited to take part in an advisory group for Myeloma UK looking at their research strategy. Travel and subsistence expenses will be paid by Myeloma UK. No honorarium or other payment will be received.	Personal pecuniary Non specific	Declare and can participate.
Monica Morris	Will receive reimbursement of travel	Personal pecuniary Non	Declare and can participate.

<b>Name</b>	<b>Interest declared</b>	<b>Type of interest</b>	<b>Decision</b>
	and subsistence expenses from Celgene for attending the Myeloma Academy educational event in Vienna	specific	
Monica Morris	Will receive an honorarium from Novartis for attending a nursing advisory board meeting on Panobinostat	Personal pecuniary Non specific	Declare and can participate.
Monica Morris	Acts as a reviewer for the myeloma section of the Cancer Research UK patient information website (CancerHelp UK). This review is done every 2 years. Receives a small payment from CRUK.	Personal Pecuniary Non-specific	Declare and can participate.